<DOC>
	<DOCNO>NCT00423930</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth head neck cancer block blood flow tumor . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving cisplatin bevacizumab together intensity-modulated radiation therapy may kill tumor cell . PURPOSE : This phase II trial study side effect well give cisplatin bevacizumab together intensity-modulated radiation therapy work treat patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Cisplatin , Bevacizumab , Intensity-Modulated Radiation Therapy Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year progression-free survival patient stage III IV squamous cell carcinoma head neck treat chemoradiotherapy comprise cisplatin , bevacizumab , intensity-modulated radiotherapy . - Determine safety tolerability regimen patient . Secondary - Determine median overall survival patient treat regimen . OUTLINE : - Chemoradiotherapy : Patients receive cisplatin IV 1 hour day 1 , 2 , 22 , 23 , 43 , 44 bevacizumab IV 30-90 minute day 1 , 22 , 43 . Patients also undergo intensity-modulated radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . Treatment continue absence disease progression unacceptable toxicity . Between 3-4 month completion chemoradiotherapy , patient undergo evaluation . Patients clinical evidence residual , progressive , persistent disease may eligible undergo neck surgery discretion physician . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Stage III/IV HNSCC without distant metastasis , previously untreated . Patients stage II squamous cell carcinoma hypopharynx also eligible . Adequate renal function , serum creatinine ≤ 1.5 mg/dL . Patients serum creatinine &gt; 1.5 mg/dL may eligible calculated creatinine clearance ≥ 55 ml/min Cockcroft Gault equation ( 24hour urine collection ) . Age ≥ 18 year Karnofsky performance status ≥70 % Adequate bone marrow function : absolute neutrophil count ≥ 1,500/μl , platelet ≥ 100,000/μl , hemoglobin ≥ 9 gm/dl Adequate hepatic function : Total bilirubin ≤ 1.5 X UNL ( patient Gilbert 's syndrome cause hyperbilirubinemia may eligible total bilirubin ≤ 2.5 X UNL ) , aspartate aminotransferase ( AST ) ≤ 2.5 X UNL , alanine aminotransferase ( ALT ) ≤ 2.5 X UNL , alkaline phosphatase ≤ 2.5 X UNL . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients must ability understand willingness sign write informed consent document . Prior chemotherapy radiation therapy HNSCC Prior treatment bevacizumab agent specifically target VEGF Other active malignancy , indolent malignancy investigator determines unlikely interfere treatment efficacy analysis . For example , patient nonmelanoma skin cancer , situ carcinoma cervix , prostate cancer within current biochemical ( PSA ) radiologic evidence disease may enroll . Patients nasopharyngeal carcinoma Patients receive amifostine part radiation treatment plan Patients skin breakdown/ulceration ( CTCAE version 3.0 , grade 2 high ) . Patients hear loss require hear aid intervention ( i.e . interfere clinical significant way activity daily live ) . Patients multifocal peripheral sensory alteration paresthesias ( include tingle ) interfere function , per patient report ( example : activity daily live ) . History arterial thromboembolic event , include transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , unstable angina , myocardial infarction ( MI ) within last 3 year . Urine protein : creatinine ( UPC ) ratio ≥ 1.0 screening . A random urine sample collect . Total protein ( mg/dL ) spot creatinine ( mg/dL ) order sample . The UPC ratio calculate result test . International normalized ratio ( INR ) &gt; 1.5 activate partial thromboplastin time ( aPTT ) &gt; 1.5 X upper limit normal ( UNL ) , Current use warfarin , current use heparin lowmolecular weight heparin , chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function . Treatment dipyramidole ( Persantine ) , ticlopidine ( Ticlid ) , clopidogrel ( Plavix ) cilostazol ( Pletal ) allow . Patients gross hemoptysis hematemesis ( define bright red blood 1 teaspoon ) within 1 month prior Day 1 protocol treatment exclude trial . Patients incidental blood mixed phlegm exclude . Esophageal varix , nonhealing ulcer , wound , bone fracture exclusion criterion . However , patient skin breakdown overlie malignant neck lymphadenopathy may eligible , discretion investigator . Anatomic lesion increase risk serious hemorrhage , encasement invasion major blood vessel primary tumor and/or involve lymph node Blood pressure &gt; 150/100 mmHg New York Heart Association ( NYHA ) Grade II great congestive heart failure . Clinically significant peripheral vascular disease History bleed diathesis hemorrhagic disorder , coagulopathy . Major surgical procedure significant traumatic injury within 28 day prior treatment bevacizumab Core biopsy within 15 day prior treatment bevacizumab . Minor surgical procedure fine needle aspiration placement percutaneous gastrostomy tube ( PEG ) less 7 day prior treatment bevacizumab History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior enrollment . Inability comply study and/or followup procedure Women pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>tongue cancer</keyword>
</DOC>